Research programme: nanomedicines - Pfizer/Merck & Co

Drug Profile

Research programme: nanomedicines - Pfizer/Merck & Co

Alternative Names: KSP Accurin™ - Pfizer/Merck & Co; KSP inhibitors - Pfizer/Merck & Co; PLK1 Accurin™ - Pfizer/Merck & Co; PLK1 inhibitors - Pfizer/Merck & Co

Latest Information Update: 25 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BIND Therapeutics; Merck & Co
  • Developer Merck & Co; Pfizer
  • Class
  • Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
  • 06 Nov 2014 BIND Therapeutics and Merck & Co sign an agreement for the development of nanomedicines for cancer
  • 06 Nov 2014 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top